FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2991063889> ?p ?o ?g. }

• W2991063889 endingPage "106" @default.
• W2991063889 startingPage "99" @default.
• W2991063889 abstract "Recent advances in recombinant adeno-associated virus (rAAV) gene therapy for choroideremia show gene replacement to be a promising approach. It is, however, well known that contact of vector solution with plastic materials in the surgical device may result in non-specific adsorption with resulting loss of physical titer and/or level of protein expression and activity. Here we assessed the biocompatibility and stability of rAAV2-REP1 (Rab Escort Protein-1) before and following passage through the injection device over a period of time to mimic the clinical scenario. Three identical devices were screened using two concentrations of vector: high (1E+12 DNase-resistant particles [DRP]/mL) and low (1E+11 DRP/mL), to mimic high- and low-dose administrations of vector product. The low dose was prepared using either formulation buffer that contained 0.001% of a non-ionic surfactant (PF68) or balanced salt solution (BSS). We observed significant losses in the genomic titer of samples diluted with BSS for all time points. The addition of 0.001% PF68 did not, however, affect rAAV physical titer, or REP1 protein expression and biological activity. Hence we observed that neither the genomic titer nor the biological activity of a rAAV2-REP1-containing solution was affected following passage through the surgical device when PF68 was present as a surfactant and this was maintained over a period up to 10 h. Recent advances in recombinant adeno-associated virus (rAAV) gene therapy for choroideremia show gene replacement to be a promising approach. It is, however, well known that contact of vector solution with plastic materials in the surgical device may result in non-specific adsorption with resulting loss of physical titer and/or level of protein expression and activity. Here we assessed the biocompatibility and stability of rAAV2-REP1 (Rab Escort Protein-1) before and following passage through the injection device over a period of time to mimic the clinical scenario. Three identical devices were screened using two concentrations of vector: high (1E+12 DNase-resistant particles [DRP]/mL) and low (1E+11 DRP/mL), to mimic high- and low-dose administrations of vector product. The low dose was prepared using either formulation buffer that contained 0.001% of a non-ionic surfactant (PF68) or balanced salt solution (BSS). We observed significant losses in the genomic titer of samples diluted with BSS for all time points. The addition of 0.001% PF68 did not, however, affect rAAV physical titer, or REP1 protein expression and biological activity. Hence we observed that neither the genomic titer nor the biological activity of a rAAV2-REP1-containing solution was affected following passage through the surgical device when PF68 was present as a surfactant and this was maintained over a period up to 10 h." @default.
• W2991063889 created "2019-12-05" @default.
• W2991063889 creator A5014542348 @default.
• W2991063889 creator A5022251818 @default.
• W2991063889 creator A5044263098 @default.
• W2991063889 creator A5046326117 @default.
• W2991063889 creator A5053499612 @default.
• W2991063889 creator A5055338875 @default.
• W2991063889 date "2020-06-01" @default.
• W2991063889 modified "2023-10-15" @default.
• W2991063889 title "Inclusion of PF68 Surfactant Improves Stability of rAAV Titer when Passed through a Surgical Device Used in Retinal Gene Therapy" @default.
• W2991063889 cites W1975968351 @default.
• W2991063889 cites W2035101755 @default.
• W2991063889 cites W2051159468 @default.
• W2991063889 cites W2086498377 @default.
• W2991063889 cites W2101222467 @default.
• W2991063889 cites W2107264642 @default.
• W2991063889 cites W2111638101 @default.
• W2991063889 cites W2126115955 @default.
• W2991063889 cites W2137222303 @default.
• W2991063889 cites W2141575938 @default.
• W2991063889 cites W2342947338 @default.
• W2991063889 cites W2502954326 @default.
• W2991063889 cites W2736065260 @default.
• W2991063889 cites W2745518150 @default.
• W2991063889 cites W2795169405 @default.
• W2991063889 cites W2808763245 @default.
• W2991063889 cites W2810681605 @default.
• W2991063889 cites W2890721979 @default.
• W2991063889 cites W2893026352 @default.
• W2991063889 doi "https://doi.org/10.1016/j.omtm.2019.11.005" @default.
• W2991063889 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6931089" @default.
• W2991063889 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31890744" @default.
• W2991063889 hasPublicationYear "2020" @default.
• W2991063889 type Work @default.
• W2991063889 sameAs 2991063889 @default.
• W2991063889 citedByCount "12" @default.
• W2991063889 countsByYear W29910638892021 @default.
• W2991063889 countsByYear W29910638892022 @default.
• W2991063889 countsByYear W29910638892023 @default.
• W2991063889 crossrefType "journal-article" @default.
• W2991063889 hasAuthorship W2991063889A5014542348 @default.
• W2991063889 hasAuthorship W2991063889A5022251818 @default.
• W2991063889 hasAuthorship W2991063889A5044263098 @default.
• W2991063889 hasAuthorship W2991063889A5046326117 @default.
• W2991063889 hasAuthorship W2991063889A5053499612 @default.
• W2991063889 hasAuthorship W2991063889A5055338875 @default.
• W2991063889 hasBestOaLocation W29910638891 @default.
• W2991063889 hasConcept C104317684 @default.
• W2991063889 hasConcept C111599444 @default.
• W2991063889 hasConcept C135983454 @default.
• W2991063889 hasConcept C153911025 @default.
• W2991063889 hasConcept C159047783 @default.
• W2991063889 hasConcept C185592680 @default.
• W2991063889 hasConcept C2522874641 @default.
• W2991063889 hasConcept C2778107364 @default.
• W2991063889 hasConcept C2779418775 @default.
• W2991063889 hasConcept C32470452 @default.
• W2991063889 hasConcept C32611913 @default.
• W2991063889 hasConcept C40767141 @default.
• W2991063889 hasConcept C55493867 @default.
• W2991063889 hasConcept C58226133 @default.
• W2991063889 hasConcept C86803240 @default.
• W2991063889 hasConcept C92087593 @default.
• W2991063889 hasConceptScore W2991063889C104317684 @default.
• W2991063889 hasConceptScore W2991063889C111599444 @default.
• W2991063889 hasConceptScore W2991063889C135983454 @default.
• W2991063889 hasConceptScore W2991063889C153911025 @default.
• W2991063889 hasConceptScore W2991063889C159047783 @default.
• W2991063889 hasConceptScore W2991063889C185592680 @default.
• W2991063889 hasConceptScore W2991063889C2522874641 @default.
• W2991063889 hasConceptScore W2991063889C2778107364 @default.
• W2991063889 hasConceptScore W2991063889C2779418775 @default.
• W2991063889 hasConceptScore W2991063889C32470452 @default.
• W2991063889 hasConceptScore W2991063889C32611913 @default.
• W2991063889 hasConceptScore W2991063889C40767141 @default.
• W2991063889 hasConceptScore W2991063889C55493867 @default.
• W2991063889 hasConceptScore W2991063889C58226133 @default.
• W2991063889 hasConceptScore W2991063889C86803240 @default.
• W2991063889 hasConceptScore W2991063889C92087593 @default.
• W2991063889 hasFunder F4320319990 @default.
• W2991063889 hasLocation W29910638891 @default.
• W2991063889 hasLocation W29910638892 @default.
• W2991063889 hasLocation W29910638893 @default.
• W2991063889 hasLocation W29910638894 @default.
• W2991063889 hasOpenAccess W2991063889 @default.
• W2991063889 hasPrimaryLocation W29910638891 @default.
• W2991063889 hasRelatedWork W1500504842 @default.
• W2991063889 hasRelatedWork W1587611090 @default.
• W2991063889 hasRelatedWork W1602083480 @default.
• W2991063889 hasRelatedWork W1965116784 @default.
• W2991063889 hasRelatedWork W2348353955 @default.
• W2991063889 hasRelatedWork W2398706404 @default.
• W2991063889 hasRelatedWork W2804873831 @default.
• W2991063889 hasRelatedWork W3015343921 @default.
• W2991063889 hasRelatedWork W4212795668 @default.
• W2991063889 hasRelatedWork W4313580290 @default.
• W2991063889 hasVolume "17" @default.

• next